Navigation Links
Initial Trial of Sanaria's Malaria Vaccine Yields Positive Results
Date:9/8/2011

to entirely prevent infection with Plasmodium falciparum malaria has been established and will be rigorously pursued."  

Internationally renowned malariologist and vaccinologist Professor Michael Good of Griffith University, Australia says, "The results presented in Science represent an enormous step toward the development of the highly effective malaria preventative vaccine generally recognized as essential for the elimination and eventually the eradication of the malaria scourge."

About Sanaria Inc.:

Sanaria Inc. was founded in 2003. The Company's mission is to develop and commercialize whole-parasite malaria vaccines that confer high-level, long-lasting protection against Plasmodium falciparum, the parasite responsible for most of the malaria-associated severe illness and death worldwide, and the other parasites that cause human malaria.  Sanaria's corporate headquarters, administrative, research, development, and manufacturing operations are located in Rockville, Maryland. The Company's website is http://www.sanaria.com.

Except for historical information, this news release contains certain forward-looking statements that involve known and unknown risk and uncertainties, which may cause actual results to differ materially from any future results, performance or achievements expressed or implied by the statements made. Such statements include the availability of an effective vaccine, the expectations for conquering malaria, beliefs concerning the suitability of a successful vaccine, and the establishment of a path toward prevention of infection. These forward-looking statements are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include, without limitation, the Company's ability to raise sufficient funds, the regulatory approval process, dependence on third
'/>"/>

SOURCE Sanaria Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
2. MacuSight(TM) Announces Positive Initial Results From Phase 1 Study of Sirolimus in Diabetic Macular Edema
3. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
4. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
5. Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response
6. Treatment with PEGASYS(R)/COPEGUS(TM) Provides Hope for Hepatitis C Patients Whose Infection Did Not Initially Respond to Peg-Intron(R)/Ribavirin
7. Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases
8. Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood
9. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
10. ATS Medical Announces Initial Clinical Results of Stand-Alone Atrial Fibrillation Procedures Using ATS CryoMaze Product Line
11. Perioperative Eloxatin(R)-Based Regimen Significantly Reduced the Risk of Relapse Versus Surgery Alone in Eligible Colorectal Cancer Patients with Initially Resectable Liver Metastases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... 2013  Grifols, ein globales Unternehmen der ... , Spanien, präsentierte die Ergebnisse einer ... von PROLASTIN©-C (Alpha1-Proteinasehemmer [human]) den Spiegel des ... ein Niveau anhebt, das innerhalb des für ... ist eine lebensbedrohliche, genetische Erkrankung, bei der ...
(Date:5/22/2013)... May 22, 2013 Varian Medical Systems ... received 510(k) clearance from the U.S. Food and ... processing workstation that combines radio frequency (RF) and ... Nexus DRF Digital X-Ray Imaging System™ has the ... receptors, including CCD cameras and commercially available flat-panel ...
(Date:5/22/2013)... , May 22, 2013 /PRNewswire-iReach/ -- MarketReportsOnline.com announces ... Pharmaceutical Guidebook Series (4) 2013 Edition Material and ... Imported Drug Registration: A Guidebook of Registration Application ... " to its online database. The ... medicines are always regarded by occidental as mysterious ...
Breaking Medicine Technology:Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 2Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 3Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 4Varian Medical Systems Receives FDA 510(k) Clearance of its Nexus DRF Digital X-Ray Imaging System 2China Pharmaceutical Market Guidebook Series (4) 2013 Report 2China Pharmaceutical Market Guidebook Series (4) 2013 Report 3China Pharmaceutical Market Guidebook Series (4) 2013 Report 4China Pharmaceutical Market Guidebook Series (4) 2013 Report 5
... June 28, 2011 The Mirixa Corporation and ... are pleased to announce that MirixaPro(SM), a Web-based ... patient care service delivery, will be deployed in ... agreement enabling CACDS to use a scalable, localized ...
... 2011 ,   The ... range of,new clinical data. The "Late-Breaking Clinical Trials" were ... SHPT study,(Evaluation of the Effectiveness of Paricalcitol Versus Cinacalcet,With ... June the,principal investigator of this study, Prof. Markus Ketteler,(Coburg, ...
Cached Medicine Technology:Mirixa and CACDS Sign Agreement for Clinical Service Delivery Platform 2Mirixa and CACDS Sign Agreement for Clinical Service Delivery Platform 3Update on IMPACT Study Results 2
(Date:5/22/2013)... May 22, 2013 Spinal Elements, ... corporate headquarters in Carlsbad to 3115 Melrose Drive, ... from the company’s continued and projected growth and ... 8,500 square feet to over 40,000 square feet. ... Spinal Elements, indicated, “Our investment in these state-of-the-art ...
(Date:5/22/2013)... Lawrenceville, NJ and Los Angeles, CA (PRWEB) May 22, ... chairman of the board, The J. M. Smucker Company, ... GS1 Lifetime Achievement Awards yesterday at the GS1 General ... Los Angeles, California. Mr. Smucker and Mr. Wegman were ... adoption of GS1 Standards - the most broadly used ...
(Date:5/22/2013)... News) -- Children who are physically, sexually or emotionally ... later in life, a new review suggests. British ... likely to be obese as adults. They concluded that ... factor for obesity. "We found that being maltreated ... in adult life," study author Dr. Andrea Danese, a ...
(Date:5/22/2013)... cancer. However, when existing drugs boost p53, only a few tumors ... the journal Cell Reports shows how: tumors that live ... protein p21 than the protein PUMA; tumors that die have more ... shows a handful of genes that control this ratio. , "The ... Tumors turn it off and then they can avoid controls that ...
(Date:5/22/2013)... May 22, 2013 The new 13-valent pneumococcal conjugate ... previous version used prior to 2010, the 7-valent pneumococcal ... published today in Vaccine . , The U.S. ... in 2010 after a series of trials. These trials ... of pneumococcal types than the previously used PCV7, did ...
Breaking Medicine News(10 mins):Health News:Spinal Elements®, Inc. Relocates Corporate Headquarters in Carlsbad 2Health News:Tim Smucker and Danny Wegman Honored With GS1 Lifetime Achievement Awards 2Health News:Tim Smucker and Danny Wegman Honored With GS1 Lifetime Achievement Awards 3Health News:Abused Children at Risk for Obesity as Adults: Study 2Health News:Study details genes that control whether tumors adapt or die when faced with p53 activating drugs 2Health News:Study finds new pneumococcal vaccine appears to be as safe as previously used vaccine 2
... low cost cutting-edge technologies that can be used to maximize ... had strokes, head injuries and other causes of aphasia re-engage ... Join an award winning speech-language pathologist who ... with aphasia. , , Research has shown that technology ...
... of broken bones , THURSDAY, June 11 (HealthDay News) -- ... person at greater risk for broken bones, a new study ... Mayo Clinic researchers revealed that the person fractured a bone ... breaks occurred in the bones of the hands and feet, ...
... ... new media age. , ... MA (Vocus) June 11, 2009 -- From cyberbullying and violent video games to social networking ... children. To help parents navigate this new and changing landscape, the Center on Media ...
... BOSTON, June 11 GlobalEquityReport.com is ... Investors who are interested in stocks on the move and in ... http://www.GlobalEquityReport.com , , Today,s ... Generex Biotechnology, Corp. (Nasdaq: GNBT ), Cell Therapeutics, Inc. ...
... realistic computer game will soon be used to help ... The Virtual Dental Implant Training Simulation Program is ... treatment protocols. It was designed by Medical College of ... Ltd., a developer of game-based technology for training, experimentation ...
... The Nintendo Wii may help treat symptoms of Parkinson,s ... says. Parkinson,s disease is a degenerative disease ... popular computer game console, which simulates various sports and ... but he found additional benefits as well. "The ...
Cached Medicine News:Health News:Innovative Interventions for Aphasia - Free Live and Recorded Webinar 2Health News:Might Weight-Loss Surgery Lead to Fractures? 2Health News:Center on Media and Child Health Launches "Ask the Mediatrician" 2Health News:Center on Media and Child Health Launches "Ask the Mediatrician" 3Health News:GlobalEquityReport.com Issues Cancer Stocks On The Move Today: HEB, GNBT, CTIC, CTHP, DNDN 2Health News:Simulation helps students learn dental implant procedures 2Health News:Simulation helps students learn dental implant procedures 3Health News:Wii-hab may enhance Parkinson's treatment 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: